<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2105245331
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SUNLENCA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LENACAPAVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        12201.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ROTTENDORF PHARMA GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ROTTENDORF PHARMA GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gilead Sciences, Inc
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SUNLENCA contains the active substance lenacapavir. This is an antiretroviral medicine known as a capsid inhibitor.</p><p>&nbsp;</p><p>SUNLENCA is a prescription medicine that <strong>is</strong> <strong>used with other human immunodeficiency virus-1 (HIV-1) medicines</strong> to treat HIV-1 infection in adults:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have received HIV-1 medicines in the past, <strong>and</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have HIV-1 virus that is resistant to many HIV-1 medicines, <strong>and</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; whose current HIV-1 medicines are failing. Your HIV-1 medicines may be failing because the HIV-1 medicines are not working or no longer work, you are not able to tolerate the side effects, or there are safety reasons why you cannot take them.</p><p>&nbsp;</p><p>HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).</p><p>&nbsp;</p><p>Treatment with SUNLENCA in combination with other antiretrovirals reduces the amount of HIV in your body. This will improve the function of your immune system (the body&rsquo;s natural defences) and reduce the risk of developing illnesses linked to HIV infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take SUNLENCA</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to lenacapavir or any of the other ingredients of this medicine (listed in section 6)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking any of these medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rifampicin</strong> used to treat some bacterial infections such as tuberculosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>carbamazepine, phenytoin</strong>, used to prevent seizures</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>St. John&rsquo;s wort</strong> (Hypericum perforatum), a herbal remedy used for depression and anxiety</p><p>&nbsp;</p><p><strong>&agrave;</strong> <strong>Do not take SUNLENCA and tell your doctor immediately </strong>if you think this applies to you.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions </strong></p><p><strong>&nbsp;</strong></p><p><strong>Talk to your doctor before taking SUNLENCA</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Talk to your doctor or pharmacist if you have ever had severe liver disease, or if tests have shown problems with your liver.</strong> Your doctor will carefully consider whether to treat you with SUNLENCA.</p><p><strong>&nbsp;</strong></p><p><strong>While you are using SUNLENCA</strong></p><p><strong>&nbsp;</strong></p><p>Once you start using SUNLENCA, look out for:</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Signs of inflammation </strong>or<strong> infection</strong>.</p><p><strong>&nbsp;</strong></p><p><strong>&agrave;</strong><strong> If you notice any of these symptoms, tell your doctor immediately.</strong> For more information, see section 4, <em>Possible side effects</em>.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p><strong>&nbsp;</strong></p><p>Do not give this medicine to children under 18 years of age. The use of SUNLENCA in patients aged under 18 has not yet been studied, so it is not known how safe and effective the medicine is in this age group.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and SUNLENCA</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. SUNLENCA may interact with other medicines. This may keep SUNLENCA or other medicines from working properly, or may make side effects worse. In some cases, your doctor may need to adjust your dose or check your blood levels.</p><p>&nbsp;</p><p><strong>Medicines that must never be taken with SUNLENCA:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rifampicin </strong>used to treat some bacterial infections, such as tuberculosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>carbamazepine, phenytoin</strong>,<strong> </strong>used to prevent seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>St. John&rsquo;s wort (<em>Hypericum perforatum</em>)</strong>, a herbal remedy used for depression and anxiety</p><p>&nbsp;</p><p><strong>&agrave;</strong> If you are taking any of these medicines, <strong>do not take SUNLENCA and tell your doctor immediately</strong>.</p><p>&nbsp;</p><p><strong>Talk to your doctor in particular if you are taking:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics containing:</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticonvulsants used to treat epilepsy and prevent seizures (fits), containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oxcarbazepine or phenobarbital</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat HIV, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atazanavir/cobicistat, efavirenz, nevirapine, tipranavir/ritonavir or etravirine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat migraine headache, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dihydroergotamine or ergotamine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicine used to treat impotence and pulmonary hypertension, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sildenafil or tadalafil</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicine used to treat<strong> </strong>impotence, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vardenafil</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corticosteroids (also known as &lsquo;steroids&rsquo;) taken orally or given by injection used to treat allergies, inflammatory bowel diseases, and other various illnesses involving inflammations in your body, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dexamethasone or hydrocortisone/cortisone</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to lower<strong> </strong>cholesterol, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lovastatin or simvastatin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antiarrhythmics used to treat heart problems, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to help you sleep, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; midazolam or triazolam.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticoagulants used to prevent and treat blood clots, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rivaroxaban, dabigatran or edoxaban</p><p>&nbsp;</p><p><strong>&agrave;</strong><strong> Tell your doctor if you are taking any of these medicines </strong>or if you start taking any of these medicines during treatment with SUNLENCA. Do not stop any treatment without contacting your doctor.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>As a precautionary measure you should avoid the use of SUNLENCA during pregnancy unless your doctor tells you otherwise.</p><p>&nbsp;</p><p>Do not breastfeed if you take SUNLENCA. You should not breastfeed if you are HIV-positive because HIV infection can be passed on to the baby through breast milk. <strong>Talk with your doctor about the best way to feed your baby during treatment with SUNLENCA.</strong></p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p><strong>&nbsp;</strong></p><p>SUNLENCA is not expected to have any effect on your ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SUNLENCA is<strong> used in combination with other antiretroviral medicines </strong>to treat HIV infection. Your doctor will advise which other medicines you need to take to treat your HIV infection, and when you need to take them.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your SUNLENCA treatment will consist of injections and tablets.</p><p>o&nbsp;&nbsp; <strong>SUNLENCA injections</strong> will be given to you by your doctor or nurse under the skin (subcutaneous injection) in your stomach-area (abdomen).</p><p>o&nbsp;&nbsp; Take <strong>SUNLENCA tablets</strong> by mouth, with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are two options (Option 1 and Option 2) to start treatment with SUNLENCA. Your doctor will decide which starting option is for you.</p><p>o&nbsp;&nbsp; If <strong>Option 1</strong> is chosen:</p><p>&sect;&nbsp; On Day 1, you will receive 2 SUNLENCA injections and take 2 SUNLENCA tablets.</p><p>&sect;&nbsp; On Day 2, you will take 2 SUNLENCA tablets.</p><p>o&nbsp;&nbsp; If <strong>Option 2</strong> is chosen:</p><p>&sect;&nbsp; On Day 1 and Day 2, you will take 2 SUNLENCA tablets each day.</p><p>&sect;&nbsp; On Day 8, you will take 1 SUNLENCA tablet.</p><p>&sect;&nbsp; On Day 15, you will receive 2 SUNLENCA injections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After completing Option 1 or Option 2, you will receive 2 SUNLENCA injections every 6 months (26 weeks) from the date of your last injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stay under the care of a doctor during treatment with SUNLENCA. <strong>It is important that you attend your planned appointments to receive your injections of SUNLENCA.</strong></p><p>&nbsp;</p><p><strong>If you take more SUNLENCA than you should</strong></p><p>&nbsp;</p><p>Contact your doctor or pharmacist immediately for advice. If you take more than the recommended dose of SUNLENCA, you may be at higher risk of side effects (see section 4, <em>Possible side effects</em>).</p><p><strong>&nbsp;</strong></p><p><strong>It is important not to miss a dose of SUNLENCA tablets.</strong></p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take your tablets</strong>, contact your doctor or pharmacist immediately.</p><p><strong>&nbsp;</strong></p><p><strong>If you vomit </strong>within 3 hours after taking SUNLENCA tablets, contact your doctor immediately and retake your scheduled tablet(s). If you vomit more than 3 hours after taking SUNLENCA you do not need to take more tablets until your next scheduled tablets or injection.</p><p>&nbsp;</p><p><strong>If you miss a SUNLENCA injection</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important that you attend <strong>your planned appointments</strong> <strong>every 6 months</strong> to receive your injections of SUNLENCA. This will help to control your HIV infection and to stop your illness from getting worse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you think you will not be able to attend your appointment for your injections, call your doctor as soon as possible to discuss your treatment options.</p><p>&nbsp;</p><p><strong>Do not stop taking SUNLENCA</strong></p><p><strong>&nbsp;</strong></p><p>Do not stop taking SUNLENCA tablets or any other antiretroviral medicines without talking to your doctor. Stopping SUNLENCA can seriously affect how future HIV treatments work.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>&nbsp;</strong></p><p><strong>Possible serious side effects: tell a doctor immediately </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Any signs of inflammation or infection. </strong>In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after HIV treatment is started. It is thought that these symptoms are due to an improvement in the body&rsquo;s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Autoimmune disorders</strong>, when the immune system attacks healthy body tissue, may also occur after you start taking medicines for HIV infection. Autoimmune disorders may occur many months after the start of treatment. Look out for any symptoms of infection or other symptoms such as:</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness beginning in the hands and feet and moving up towards the trunk of the body</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations, tremor or hyperactivity</p><p>&nbsp;</p><p><strong>&agrave;</strong><strong> </strong>If you notice these or any symptoms of inflammation or infection,<strong> tell your doctor immediately.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Common side effects</strong></p><p><em>(may affect up to 1 in 10 people)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Feeling sick </strong>(nausea)</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p><br />Store below 30&deg;C.</p><p><br />Store in the original package in order to protect from moisture.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is lenacapavir. Each tablet contains lenacapavir sodium equivalent to 300&nbsp;mg lenacapavir.</p><p>&nbsp;</p><p>The other ingredients are</p><p><strong>&nbsp;</strong></p><p><em>Tablet core</em></p><p>Copovidone, croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, and poloxamer 407.</p><p><em>&nbsp;</em></p><p><em>Film-coating</em></p><p>Iron oxide black, iron oxide red, iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	SUNLENCA film-coated tablets are beige, capsule-shaped, film-coated tablets, debossed with “GSI” on one side of the tablet and “62L” on the other side of the tablet. SUNLENCA comes in a blister of 5 or 4 tablets surrounded by a blister card. The blister is placed within a foil pouch. The foil pouch contains a silica gel desiccant that must be kept in the foil pouch to help protect your tablets. The silica gel is contained in a separate sachet or canister and is not to be swallowed.
	
	SUNLENCA is available in packs containing 5 or 4 tablets.
	Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Gilead Sciences, Inc.</p><p>333 Lakeside Drive,</p><p>Foster City, CA 94404</p><p>United States</p><p>&nbsp;</p><p><strong>Final Batch Release Site</strong></p><p>Gilead Sciences, Inc.</p><p>333 Lakeside Drive,</p><p>Foster City, CA 94404</p><p>United States</p><p><strong>&nbsp;</strong></p><p><strong>Bulk Manufacturer</strong></p><p>Rottendorf Pharma GmbH<br />Ostenfelder Strasse 51-61,<br />Ennigerloh 59320,<br />Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in 01/2023
	SA-FEB2023-US-DEC2022-EU-AUG2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي صنلينكا على المادة الفعالة ليناكابافير. وهو دواء مضاد للفيروسات القهقرية يُعرف باسم مثبط الغلاف الفيروسي (القُفيصة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;ويصرف صنلينكا بوصفة طبية و<strong>يُستخدم مع أدوية أخرى لفيروس نقص المناعة البشرية -1 (</strong><strong>HIV-1</strong><strong>)</strong> <strong>وذلك </strong>لعلاج عدوى HIV-1 عند البالغين:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذين تلقوا أدوية لعلاج فيروس نقص المناعة البشرية 1 سابقًا، <strong>و</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذين لديهم فيروس نقص المناعة البشرية -1 المقاوم للعديد من أدوية نقص المناعة البشرية -1، <strong>و</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذين لم تستطع أدويتهم الحالية علاج فيروس نقص المناعة البشرية -1. قد لا تستطيع أدويتك الخاصة بفيروس نقص المناعة البشرية -1 القيام بالمعالجة؛ لأن أدوية نقص المناعة البشرية -1 لا تعمل أو لم تُعد تعمل، أو لأنك غير قادر على تحمل &nbsp;الأعراض الجانبية، أو ثمة أسباب تتعلق بالسلامة تمنعك من تناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن فيروس نقص المناعة البشرية -1 هو الفيروس المسبب لمتلازمة نقص المناعة المكتسب (الإيدز).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يقلل العلاج بصنلينكا بالاشتراك مع مضادات الفيروسات القهقرية الأخرى من كمية فيروس نقص المناعة البشرية في جسمك. وسيؤدي ذلك إلى تحسين وظيفة الجهاز المناعي (دفاعات الجسم الطبيعية)، وتقليل خطر الإصابة بأمراض مرتبطة بعدوى فيروس نقص المناعة البشرية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول صنلينكا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه ليناكابافير أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تتناول أي من هذه الأدوية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريفامبيسين</strong> الذي يُستخدم لعلاج بعض العدوى البكتيرية مثل السل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كاربامازيبين والفينيتوين</strong> المستخدمان لمنع النوبات التشنجية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نبتة سانت جون </strong>(نبتة القديس يوحنا)، وهي علاج عشبي يستخدم لعلاج الاكتئاب والقلق</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&szlig;</strong> <strong>لا تتناول صنلينكا وأخبر طبيبك على الفور </strong>إذا كنت تعتقد أن أيا مما سبق ينطبق عليك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;تحدث إلى طبيبك قبل تناول صنلينكا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تحدث إلى طبيبك أو الصيدلي إذا كنت تعاني من مرض كبدي حاد، أو إذا أظهرت الفحوصات وجود مشاكل في الكبد. </strong>سيفكر طبيبك بعناية فيما إذا كان سيعالجك بدواء صنلينكا أم لا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>خلال استخدامك صنلينكا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">بمجرد أن تبدأ في استخدام صنلينكا، انتبه لوجود ما يلي:</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>علامات التهاب</strong> أو <strong>عدوى</strong>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&szlig;</strong> <strong> إذا لاحظت أيًا من هذه الأعراض، أخبر طبيبك على الفور.</strong> لمزيد من المعلومات، &nbsp;راجع القسم 4، <em>&nbsp;الأعراض الجانبية المحتملة</em>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا تعط هذا الدواء للأطفال أقل من 18 عامًا. لم يُدرس بعد استخدام صنلينكا في المرضى الذين تقل أعمارهم عن 18 عامًا، لذلك لا يُعرف مدى أمان وفعالية الدواء في هذه الفئة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وصنلينكا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. قد يتفاعل دواء صنلينكا مع أدوية أخرى. مما قد يمنع صنلينكا أو الأدوية الأخرى من العمل بشكل صحيح، أو قد يزيد سوء الأعراض الجانبية. في بعض الحالات، قد يحتاج طبيبك إلى تعديل جرعتك أو فحص مستويات الدواء في دمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية التي لا يجب تناولها مع صنلينكا:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريفامبيسين</strong> الذي يُستخدم لعلاج بعض العدوى البكتيرية، مثل السل</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>كاربامازيبين والفينيتوين </strong>المستخدمان لمنع النوبات التشنجية</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نبتة سانت جون <em>(نبتة القديس يوحنا)</em></strong>، وذلك علاج عشبي يستخدم لعلاج الاكتئاب والقلق</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&szlig;</strong> إذا كنت تتناول أيًا من هذه الأدوية، <strong>فلا تتناول صنلينكا وأخبر طبيبك على الفور</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحدث إلى طبيبك تحديدًا إذا كنت تتناول:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية التي تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابوتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مضادات الاختلاج المستخدمة لعلاج الصرع ومنع النوبات التشنجية (النوبات)، والتي تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوكسكاربازيبين أو الفينوباربيتال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج فيروس نقص المناعة البشرية، والتي تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أتازانافير/كوبيسيستات، إيفافيرينز، نيفيرابين، تيبرانافير/ريتونافير أو إيترافيرين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج الصداع النصفي (الشقيقة) والتي تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثنائي هيدروإرغوتامين أو إرغوتامين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الدواء المستخدم لعلاج العجز الجنسي وارتفاع ضغط الدم الرئوي، والذي يحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلدينافيل أو تادالافيل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء المستخدم لعلاج العجز الجنسي، والذي يحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاردنافيل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات (المعروفة أيضًا باسم &quot;الستيرويدات&quot;) التي تؤخذ عن طريق الفم أو عن طريق الحقن وتُستخدم لعلاج الحساسية، وأمراض الأمعاء الالتهابية، وغيرها من الأمراض المختلفة التي تنطوي على التهابات في الجسم، والتي تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديكساميثازون أو هيدروكورتيزون/كورتيزون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لخفض الكوليسترول، والتي تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوفاستاتين أو سيمفاستاتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات اضطراب النظم المستخدمة في علاج أمراض القلب، والتي تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديجوكسين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لمساعدتك على النوم، والتي تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميدازولام أو تريازولام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التخثر المستخدمة لمنع وعلاج جلطات الدم، وتحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفاروكسابان أو دابيغاتران أو إدوكسابان</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&szlig;</strong> <strong>أخبر طبيبك إذا كنت تتناول أيًا من هذه الأدوية</strong> أو إذا بدأت في تناول أي من هذه الأدوية خلال العلاج بصنلينكا. لا تتوقف عن أي علاج دون الاتصال بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة، أو تعتقدين أنك حامل أو تخططين للإنجاب، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كإجراء وقائي، يجب عليكِ تجنب استخدام صنلينكا في أثناء الحمل ما لم يخبرك طبيبك بخلاف ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ترضعي رضاعة طبيعية إذا كنتِ تتناولين صنلينكا. لا يجب أن ترضعي طفلكِ رضاعة طبيعية إذا كانت نتائج فحص فيروس نقص المناعة البشرية إيجابية لديكِ؛ لأن عدوى فيروس نقص المناعة البشرية يمكن أن تنتقل إلى الطفل من خلال حليب الثدي. <strong>تحدثي مع طبيبك حول أفضل طريقة لإرضاع طفلكِ في أثناء العلاج بصنلينكا.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ليس من المتوقع أن يكون لصنلينكا أي تأثير على قدرتك على القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يستخدم صنلينكا <strong>بالاشتراك مع الأدوية المضادة للفيروسات القهقرية الأخرى</strong> لعلاج عدوى فيروس نقص المناعة البشرية. سينصح طبيبك بالأدوية الأخرى التي تحتاج إلى تناولها لعلاج عدوى فيروس نقص المناعة البشرية لديك، ومتى تحتاج إلى تناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يتألف علاج صنلينكا الخاص بك من حقن وأقراص.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;سيعطيك الطبيب أو الممرضة <strong>حقن صنلينكا</strong> تحت الجلد (الحقن تحت الجلد) في منطقة المعدة (البطن).</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تناول <strong>أقراص صنلينكا</strong> عن طريق الفم، مع الطعام أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يوجد خياران (الخيار 1 والخيار 2) لبدء العلاج مع صنلينكا. سيقرر طبيبك خيار البدء المناسب لك.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم اختيار <strong>الخيار 1</strong>:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في اليوم الأول، سوف تأخذ حقنتين من صنلينكا وتتناول قرصين من صنلينكا.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في اليوم الثاني، ستتناول قرصين من صنلينكا.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم اختيار <strong>الخيار 2</strong>:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في اليوم الأول واليوم الثاني، ستتناول قرصين من صنلينكا كل يوم.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;في اليوم الثامن، ستتناول قرصًا واحدًا من صنلينكا.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في اليوم الخامس عشر، ستأخذ حقنتين من صنلينكا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;بعد إكمال الخيار 1 أو الخيار 2، سوف تأخذ حقنتين من صنلينكا كل 6 أشهر (26 أسبوعًا) من تاريخ آخر حقنة.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ابق تحت رعاية الطبيب في أثناء العلاج بصنلينكا. <strong>من المهم أن تحضر المواعيد المخططة لأخذ حقن صنلينكا.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما ينبغي من صنلينكا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك أو الصيدلي على الفور للحصول على المشورة. إذا كنت تأخذ أكثر من الجرعة الموصى بها من صنلينكا، فقد تكون أكثر عرضة لخطر &nbsp;الأعراض الجانبية ( راجع القسم 4، &nbsp;الأعراض الجانبية المحتملة).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>من المهم عدم تفويت جرعة من أقراص صنلينكا.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا <strong>نسيت تناول أقراصك</strong>، فاتصل بطبيبك أو الصيدلي على الفور.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا تقيأت</strong> في غضون 3 ساعات بعد تناول أقراص صنلينكا، فاتصل بطبيبك على الفور، وتناول مجددًا القرص (الأقراص) المحددة. إذا تقيأت بعد تناول صنلينكا بأكثر من 3 ساعات، فلن تحتاج إلى تناول المزيد من الأقراص حتى موعد الأقراص أو الحقن التالي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا فاتتك حقنة صنلينكا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم أن <strong>تحضر المواعيد المخطط لها كل 6 أشهر</strong> لتأخذ حقن صنلينكا. سيساعد ذلك في السيطرة على عدوى فيروس نقص المناعة البشرية لديك ومنع تفاقم مرضك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعتقد أنك لن تتمكن من حضور موعدك للحقن، فاتصل بطبيبك في أقرب وقت ممكن لمناقشة خيارات العلاج الخاصة بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;لا تتوقف عن تناول صنلينكا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا تتوقف عن تناول أقراص صنلينكا أو أية أدوية أخرى مضادة للفيروسات القهقرية دون التحدث إلى طبيبك. يمكن أن يؤثر إيقاف صنلينكا تأثيرًا خطيرًا على كيفية عمل علاجات فيروس نقص المناعة البشرية في المستقبل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في كل الأدوية، هذا الدواء يمكن أن يتسبب بأعراض جانبية، بالرغم من أنها قد لا تحدث للجميع.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية الخطيرة المحتملة: أخبر الطبيب على الفور</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;أي علامات التهاب أو عدوى</strong>. في بعض المرضى المصابين بعدوى متقدمة بفيروس نقص المناعة البشرية (الإيدز) ولديهم تاريخ من العدوى الانتهازية (العدوى التي تحدث عند الأشخاص الذين يعانون من ضعف جهاز المناعة)، قد تظهر علامات وأعراض الالتهاب من العدوى السابقة بعد وقت قصير من بدء علاج فيروس نقص المناعة البشرية. يُعتقد أن هذه الأعراض ناتجة عن تحسن الاستجابة المناعية للجسم، مما يمكّن الجسم من محاربة العدوى التي قد تكون موجودة مع عدم وجود أعراض واضحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;كما قد تحدث <strong>اضطرابات المناعة الذاتية</strong>، عندما يهاجم الجهاز المناعي أنسجة الجسم السليمة، بعد البدء في تناول الأدوية لعدوى فيروس نقص المناعة البشرية. قد تحدث اضطرابات المناعة الذاتية بعد عدة أشهر من بدء العلاج. انتبه لأي من أعراض العدوى أو أعراض أخرى مثل:</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ضعف يبدأ في اليدين والقدمين ويصعد باتجاه جذع الجسم</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;خفقان أو رعشة أو فرط نشاط</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&not;</strong> إذا لاحظت هذه الأعراض أو أي أعراض التهاب أو عدوى، <strong>فأخبر طبيبك على الفور</strong>.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;الأعراض الجانبية الشائعة</strong></p><p dir="RTL">(<em>قد تظهر في حوالي 1 من كل 10 أشخاص</em>).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الشعور بالإعياء</strong> (الغثيان)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن &nbsp;الأعراض الجانبية</strong></p><p dir="RTL">إذا تفاقم أي من &nbsp;الأعراض الجانبية، أو إذا لاحظت أي &nbsp;أعراض جانبية غير مدرجة في هذه النشرة، فيُرجى إخبار طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن &nbsp;مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق القنينة والكرتون بعد كلمة تاريخ الصلاحية (EXP). يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يخزن في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يخزن في العلبة الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم &nbsp;تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي ليناكابافير. يحتوي كل قرص على ليناكابافير صوديوم ما يعادل 300 ملغم من ليناكابافير</p><p dir="RTL">&nbsp;</p><p dir="RTL">وتكون المكونات الأخرى كما يلي</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><em>لب القرص</em></p><p dir="RTL">عبارة عن كوبوفيدون، كروسكارميلوز الصوديوم، ستيرات المغنيسيوم، مانيتول، سليلوز دقيق التبلور، وبولوكسامير 407.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>الغلاف</em></p><p dir="RTL">أكسيد الحديد الأسود، وأكسيد الحديد الأحمر، وأكسيد الحديد الأصفر، والبولي إيثيلين جلايكول، وكحول البولي فينيل، والتلك، وثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تكون أقراص صنلينكا المغلفة مطلية باللون البيج، على شكل كبسولة، محفور عليها &quot;GSI&quot; على جانب واحد و &quot;62 L&quot; على الجانب الآخر من القرص. يحتوي شريط أقراص صنلينكا على 4 أو 5 أقراص محاطة بشريط أدوية فقاعي. يوضع شريط الأقراص داخل كيس من الرقائق المعدنية. يحتوي كيس الرقائق المعدنية على مادة تجفيف من هلام السيليكا، يجب حفظها في كيس الرقائق للمساعدة في حماية أقراصك. يوضع هلام السيليكا في كيس أو علبة منفصلة ولا يجب ابتلاعها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر صنلينكا في عبوات تحتوي على 5 أو 4 أقراص.</p><p dir="RTL">قد لا تتوافر جميع أحجام العبوات في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p dir="RTL">Gilead Sciences, Inc.</p><p dir="RTL">333 Lakeside Drive,</p><p dir="RTL">Foster City, CA 94404</p><p dir="RTL">الولايات المتحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موقع إفراج التشغيلات النهائية</strong></p><p dir="RTL">Gilead Sciences, Inc.</p><p>333 Lakeside Drive,</p><p dir="RTL">Foster City, CA 94404</p><p dir="RTL">الولايات المتحدة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنعة الرئيسية</strong></p><p dir="RTL">Rottendorf Pharma GmbH<br />Ostenfelder Strasse 51-61,<br />Ennigerloh 59320,</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	 تمت مراجعة هذه النشرة في 01/2023
	SA-FEB2023-US-DEC2022-EU-AUG2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SUNLENCA 300 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains lenacapavir sodium equivalent to 300 mg of lenacapavir.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet)

Beige, capsule-shaped, film-coated tablets of dimensions 10 mm x 21 mm, debossed with “GSI” on one side of the tablet and “62L” on the other side of the tablet.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be prescribed by a physician experienced in the management of HIV infection.</p><p>&nbsp;</p><p>Prior to starting lenacapavir, the healthcare professional should carefully select patients who agree to the required injection schedule and counsel patients about the importance of adherence to scheduled dosing visits to help maintain viral suppression and reduce the risk of viral rebound and potential development of resistance associated with missed doses. In addition, the healthcare professional should counsel patients about the importance of adherence to an optimised background regimen (OBR) to further reduce the risk of viral rebound and potential development of resistance.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>&nbsp;</p><p>Initiation of treatment with lenacapavir requires SUNLENCA film-coated tablets to be taken as oral loading and SUNLENCA injection.</p><p>&nbsp;</p><p>SUNLENCA can be initiated using one of two recommended dosage regimens, see <!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US'><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>REF _Ref100823116 \h<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table&nbsp;1<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003100300030003800320033003100310036000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--> and <!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US'><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>REF _Ref100823193 \h<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table&nbsp;2<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000E0000005F005200650066003100300030003800320033003100390033000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--> below. Healthcare providers should determine the appropriate initiation regimen for the patient (see section 5.2). SUNLENCA oral tablets may be taken with or without food.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk74121961'><span style='mso-bookmark:_Ref71124302'><span
style='mso-bookmark:_Ref100823116'><span style='mso-bookmark:_Hlk88128474'></span></span></span></span><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-bookmark:_Hlk74121961'><span style='mso-bookmark:_Ref71124302'><span
style='mso-bookmark:_Ref100823116'><span style='mso-bookmark:_Hlk88128474'><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:11.0pt;
color:windowtext;font-style:normal;mso-bidi-font-style:italic'> SEQ Table \*
ARABIC <span style='mso-element:field-separator'></span></span></b></span></span></span></span><![endif]--><strong>1</strong><!--[if supportFields]><span
style='mso-bookmark:_Hlk74121961'><span style='mso-bookmark:_Ref71124302'><span
style='mso-bookmark:_Ref100823116'><span style='mso-bookmark:_Hlk88128474'></span></span></span></span><span
style='mso-element:field-end'></span><![endif]--><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended Treatment Regimen for SUNLENCA Initiation and Maintenance, Option 1</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment Time</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dosage of SUNLENCA: Initiation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>927 mg by subcutaneous injection (2 x 1.5 mL injections)</p><p>600 mg orally (2 x 300 mg tablets)</p></td></tr><tr><td style="vertical-align:top"><p>Day 2</p></td><td style="vertical-align:top"><p>600 mg orally (2 x 300 mg tablets)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dosage of SUNLENCA: Maintenance</strong></p></td></tr><tr><td style="vertical-align:top"><p>Every</p><p>6 months<sup> </sup><br />(26 weeks)<sup> a </sup><br />+/-2 weeks</p></td><td><p>927 mg by subcutaneous injection (2 x 1.5 mL injections)</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From the date of the last injection.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Ref88128966'><span style='mso-bookmark:_Ref100823193'></span></span><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-bookmark:_Ref88128966'><span style='mso-bookmark:_Ref100823193'><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:11.0pt;
color:windowtext;font-style:normal;mso-bidi-font-style:italic'> SEQ Table \*
ARABIC <span style='mso-element:field-separator'></span></span></b></span></span><![endif]--><strong>2</strong><!--[if supportFields]><span
style='mso-bookmark:_Ref88128966'><span style='mso-bookmark:_Ref100823193'></span></span><span
style='mso-element:field-end'></span><![endif]--><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended Treatment Regimen for SUNLENCA Initiation and Maintenance, Option 2</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment Time</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dosage of SUNLENCA: Initiation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>600 mg orally (2 x 300 mg tablets)</p></td></tr><tr><td style="vertical-align:top"><p>Day 2</p></td><td style="vertical-align:top"><p>600 mg orally (2 x 300 mg tablets)</p></td></tr><tr><td style="vertical-align:top"><p>Day 8</p></td><td style="vertical-align:top"><p>300 mg orally (1 x 300 mg tablet)</p></td></tr><tr><td style="vertical-align:top"><p>Day 15</p></td><td style="vertical-align:top"><p>927 mg by subcutaneous injection (2 x 1.5 mL injections)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Dosage of SUNLENCA: Maintenance</strong></p></td></tr><tr><td style="vertical-align:top"><p>Every</p><p>6 months<sup> </sup><br />(26 weeks)<sup> a </sup><br />+/-2 weeks</p></td><td><p>927 mg by subcutaneous injection (2 x 1.5 mL injections)</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From the date of the last injection.</p><p><em>&nbsp;</em></p><p><em>Missed dose </em></p><p><em>&nbsp;</em></p><p>Option 1:</p><p>If the Day 1 (600 mg) oral dose is missed by:</p><p>&bull; less than 2 days, the patient should take 600 mg as soon as possible, and 600 mg on the following day.</p><p>&bull; 2 days or more, the patient should skip the missed first oral dose, and take 600 mg as soon as possible.</p><p>&nbsp;</p><p>If the Day 2 (600 mg) oral dose is missed by:</p><p>&bull; less than 6 days, the patient should take 600 mg as soon as possible.</p><p>&bull; 6 days or more, the patient should skip the missed oral dose.</p><p>&nbsp;</p><p>Option 2:</p><p>If the Day&nbsp;2 (600&nbsp;mg) oral dose is missed by:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; less than 6 days, the patient should take 600&nbsp;mg as soon as possible, and 300&nbsp;mg on Day&nbsp;8.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6 days or more, the patient should take 600&nbsp;mg as soon as possible, and 300&nbsp;mg on Day&nbsp;15.</p><p>&nbsp;</p><p>If the Day 8 (300&nbsp;mg) oral dose is missed by:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; less than 6 days, the patient should take 300&nbsp;mg as soon as possible.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6 days or more, the patient should take 300&nbsp;mg on Day&nbsp;15.</p><p>Regardless of when the Day&nbsp;2 or Day&nbsp;8 oral dose is being taken, subcutaneous injection should be administered on Day 15 as described in Table 2.</p><p>&nbsp;</p><p>If the patient vomits within 3 hours of taking an oral dose of SUNLENCA, another oral dose should be taken. If the patient vomits more than 3 hours after taking an oral dose of SUNLENCA there is no need to take another oral dose of SUNLENCA, and the scheduled dosing regimen should continue.</p><p>&nbsp;</p><p>During the maintenance period, if more than 28 weeks have elapsed since the last injection and if clinically appropriate to continue SUNLENCA treatment, restart the initiation dosage regimen from Day 1, using either Option 1 or Option 2.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>No dose adjustment of SUNLENCA is required in elderly patients (see section&nbsp;5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>No dose adjustment of SUNLENCA is required in patients with mild, moderate, or severe renal impairment (creatinine clearance [CrCl]&nbsp;&ge;&nbsp;15&nbsp;mL/min). SUNLENCA has not been studied in patients with end stage renal disease (CrCl&nbsp;&lt;&nbsp;15&nbsp;mL/min or on renal replacement therapy) (see section&nbsp;5.2), therefore SUNLENCA should be used with caution in these patients.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of SUNLENCA is required in patients with mild or moderate hepatic impairment (Child-Pugh Class A or B). SUNLENCA has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) (see section&nbsp;5.2), therefore SUNLENCA should be used with caution in these patients.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of SUNLENCA in children under the age of 18&nbsp;years old has not been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>For oral use.</p><p>&nbsp;</p><p>SUNLENCA tablets should be taken orally with or without food (see section&nbsp;5.2). The film-coated tablet should not be chewed, crushed, or split, because the effects on lenacapavir absorption have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Co administration with strong inducers of CYP3A, P-gp, and UGT1A1, such as:
•	antimycobacterials: rifampicin
•	anticonvulsants: carbamazepine, phenytoin
•	herbal products: St. John’s wort (Hypericum perforatum)
(see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Immune Reconstitution Inflammatory Syndrome</u></p><p><u>&nbsp;</u></p><p>In HIV&nbsp;infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and <em>Pneumocystis jirovecii</em> pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary.</p><p><strong>&nbsp;</strong></p><p>Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.</p><p><u>&nbsp;</u></p><p><u>Opportunistic infections</u></p><p><u>&nbsp;</u></p><p>Patients should be advised that SUNLENCA or any other antiretroviral therapy does not cure HIV&nbsp;infection and that they may still develop opportunistic infections and other complications of HIV&nbsp;infection. Therefore, patients should remain under close clinical observation by physicians experienced in the treatment of patients with HIV&nbsp;associated diseases.</p><p>&nbsp;</p><p><u>Co‑administration of other medicinal products</u></p><p><u>&nbsp;</u></p><p>Co‑administration with medicinal products that are moderate inducers of CYP3A and P‑gp (e.g.&nbsp;efavirenz) is not recommended (see section&nbsp;4.5).</p><p>&nbsp;</p><p>Co‑administration with medicinal products that are strong inhibitors of CYP3A, P-gp, and UGT1A1 together (i.e. all 3 pathways), such as atazanavir/cobicistat is not recommended (see section&nbsp;4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of other medicinal products on the pharmacokinetics of lenacapavir</u></p><p>&nbsp;</p><p>Lenacapavir is a substrate of CYP3A, P‑gp and UGT1A1. Strong inducers of CYP3A, P‑gp, and UGT1A1, such as rifampicin, may significantly decrease plasma concentrations of lenacapavir resulting in loss of therapeutic effect and development of resistance, therefore co‑administration is contraindicated (see section&nbsp;4.3). Moderate inducers of CYP3A and P‑gp, such as efavirenz, may also significantly decrease plasma concentrations of lenacapavir, therefore co‑administration is not recommended (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Strong inhibitors of CYP3A, P‑gp and UGT1A1 together (i.e., all 3 pathways), such as atazanavir/cobicistat, may significantly increase plasma concentrations of lenacapavir, therefore co‑administration is not recommended (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Strong CYP3A4 inhibitors alone (e.g. voriconazole) or strong inhibitors of CYP3A4 and P‑gp together (e.g. cobicistat) do not result in a clinically meaningful increase in lenacapavir exposures.</p><p>&nbsp;</p><p><u>Effect of lenacapavir on the pharmacokinetics of other medicinal products</u></p><p><u>&nbsp;</u></p><p>Lenacapavir is a moderate inhibitor of CYP3A. Caution is advised if SUNLENCA is co‑administered with a sensitive CYP3A substrate with a narrow therapeutic index. Lenacapavir is not a clinically meaningful inhibitor of P‑gp and BCRP and does not inhibit OATP.</p><p>&nbsp;</p><p><strong>Table 3: Interactions between SUNLENCA and other medicinal products</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="vertical-align:top"><p><strong>Effects on concentrations. </strong></p><p><strong>Mean percent change in AUC, C<sub>max</sub></strong></p></td><td style="vertical-align:top"><p><strong>Recommendation concerning co‑administration with SUNLENCA</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTIMYCOBACTERIALS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin<sup>a,b,c </sup>(600&nbsp;mg once daily)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lenacapavir:</p><p>AUC:&nbsp;&darr;84%</p><p>C<sub>max</sub>:&nbsp;&darr;55%</p></td><td style="vertical-align:top"><p>Co‑administration is contraindicated (see&nbsp;section&nbsp;4.3).</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Co‑administration of rifabutin may decrease lenacapavir plasma concentrations, which may result in loss of therapeutic effect and development of resistance.</p></td><td style="vertical-align:top"><p>Co‑administration is not recommended (see section&nbsp;4.4).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTICONVULSANTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine</p><p>Phenytoin</p></td><td rowspan="2" style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Co‑administration of carbamazepine, oxcarbazepine, phenobarbital, or phenytoin with lenacapavir may decrease lenacapavir plasma concentrations, which may result in loss of therapeutic effect and development of resistance.</p></td><td style="vertical-align:top"><p>Co‑administration is contraindicated (see section&nbsp;4.3)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Oxcarbazepine</p><p>Phenobarbital</p></td><td style="vertical-align:top"><p>Co‑administration is not recommended (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Alternative anticonvulsants should be considered.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>HERBAL PRODUCTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>St. John&rsquo;s wort <em>(Hypericum perforatum)</em></p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Co‑administration of St.</p><p>John&rsquo;s wort may decrease lenacapavir plasma concentrations, which may result in loss of therapeutic effect and development of resistance.</p></td><td style="vertical-align:top"><p>Co‑administration is contraindicated (see&nbsp;section 4.3).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTIRETROVIRAL AGENTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir/cobicistat<sup>b,d,e</sup></p><p>(300&nbsp;mg/150&nbsp;mg once daily)</p></td><td style="vertical-align:top"><p>Lenacapavir:</p><p>AUC: &uarr; 321%</p><p>C<sub>max</sub>: &uarr;&nbsp;560%</p></td><td rowspan="3" style="vertical-align:top"><p>Co‑administration is not recommended (see section&nbsp;4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz<sup>b,d,f</sup> (600&nbsp;mg once daily)</p></td><td style="vertical-align:top"><p>Lenacapavir:</p><p>AUC:&darr;&nbsp;56%</p><p>C<sub>max</sub>:&darr;&nbsp;36%</p></td></tr><tr><td style="vertical-align:top"><p>Etravirine</p><p>Nevirapine</p><p>Tipranavir/ritonavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Co‑administration of etravirine, nevirapine, or tipranavir/ritonavir may decrease lenacapavir plasma concentrations, which may result in loss of therapeutic effect and development of resistance.</p></td></tr><tr><td style="vertical-align:top"><p>Cobicistat<sup>b,d,g</sup> (150&nbsp;mg once daily)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lenacapavir:</p><p>AUC:&nbsp;&uarr;&nbsp;128%</p><p>C<sub>max</sub>:&uarr;&nbsp;110%</p></td><td rowspan="3" style="vertical-align:top"><p>No dose adjustment of lenacapavir is required.</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir/cobicistat<sup>b,d,h</sup> (800&nbsp;mg/150&nbsp;mg&nbsp;once daily)</p></td><td style="vertical-align:top"><p>Lenacapavir:</p><p>AUC:&uarr;&nbsp;94%</p><p>C<sub>max</sub>:&uarr;&nbsp;130%</p></td></tr><tr><td style="vertical-align:top"><p>Ritonavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Co‑administation of ritonavir may increase lenacapavir plasma concentrations.</p></td></tr><tr><td style="vertical-align:top"><p>Tenofovir alafenamide<sup>d,i,j</sup> (25&nbsp;mg)</p></td><td style="vertical-align:top"><p>Tenofovir alafenamide:</p><p>AUC:&uarr;&nbsp;32%</p><p>C<sub>max</sub>:&uarr;&nbsp;24%</p><p>&nbsp;</p><p>Tenofovir<sup>k</sup>:</p><p>AUC:&uarr;&nbsp;47%</p><p>C<sub>max</sub>:&uarr;&nbsp;23%</p></td><td style="vertical-align:top"><p>No dose adjustment of tenofovir alafenamide is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ERGOT DERIVATIVES</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Dihydroergotamine</p><p>Ergotamine</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Plasma concentrations of these medicinal products may be increased when co‑administered with lenacapavir.</p></td><td style="vertical-align:top"><p>Caution is warranted when dihydroergotamine or ergotamine, is co‑administered with SUNLENCA.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Sildenafil</p><p>Tadalafil</p><p>Vardenafil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Plasma concentration of PDE-5 inhibitors may be increased when co‑administered with lenacapavir.</p></td><td style="vertical-align:top"><p>Use of PDE-5 inhibitors for pulmonary arterial hypertension: Co‑administration with tadalafil is not recommended.</p><p>&nbsp;</p><p>Use of PDE-5 inhibitors for erectile dysfunction:</p><p>Sildenafil: A starting dose of 25&nbsp;mg is recommended.</p><p>Vardenafil: No more than 5&nbsp;mg in a 24‑hour period.</p><p>Tadalafil:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For use as needed: no more than 10&nbsp;mg every 72&nbsp;hours</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For once daily use: dose not to exceed 2.5&nbsp;mg</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>CORTICOSTEROIDS (systemic)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Dexamethasone</p><p>Hydrocortisone/cortisone</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Plasma concentrations of corticosteroids may be increased when co‑administered with lenacapavir.</p></td><td style="vertical-align:top"><p>Co‑administration of SUNLENCA with corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing&#39;s syndrome and adrenal suppression.&nbsp; Initiate with the lowest starting dose and titrate carefully while monitoring for safety.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>HMG‑CoA REDUCTASE INHIBITORS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Lovastatin</p><p>Simvastatin</p></td><td rowspan="2" style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Plasma concentrations of these medicinal products may be increased when co‑administered with lenacapavir.</p></td><td style="vertical-align:top"><p>Initiate lovastatin and simvastatin with the lowest starting dose and titrate carefully while monitoring for safety (e.g. myopathy).</p></td></tr><tr><td style="vertical-align:top"><p>Atorvastatin</p></td><td style="vertical-align:top"><p>No dose adjustment of atorvastatin is required.</p></td></tr><tr><td style="vertical-align:top"><p>Pitavastatin<sup>d,i,l</sup> (2&nbsp;mg single dose; simultaneous or 3 days after lenacapavir)</p></td><td style="vertical-align:top"><p>Pitavastatin:</p><p>AUC:&harr;</p><p>C<sub>max</sub>:&harr;</p></td><td rowspan="2" style="vertical-align:top"><p>No dose adjustment of pitavastatin and rosuvastatin is required.</p></td></tr><tr><td style="vertical-align:top"><p>Rosuvastatin<sup>d,i,m</sup> (5&nbsp;mg single dose)</p></td><td style="vertical-align:top"><p>Rosuvastatin:</p><p>AUC:&uarr;&nbsp;31%</p><p>C<sub>max</sub>:&uarr;&nbsp;57%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTIARRHYTHMICS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Digoxin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Plasma concentration of digoxin may be increased when co‑administered with lenacapavir.</p></td><td style="vertical-align:top"><p>Caution is warranted and therapeutic concentration monitoring of digoxin is recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>SEDATIVES/HYPNOTICS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Midazolam<sup>d,i,n</sup> (2.5&nbsp;mg single dose; oral; simultaneous administration)</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Midazolam:</p><p>AUC:&nbsp;&uarr;&nbsp;259%</p><p>C<sub>max</sub>: &uarr;&nbsp;94%</p><p>&nbsp;</p><p>1‑hydroxymidazolam<sup>o</sup>:</p><p>AUC: &darr;&nbsp;24%</p><p>C<sub>max</sub>: &darr;&nbsp;46%</p></td><td rowspan="3" style="vertical-align:top"><p>Caution is warranted when midazolam or triazolam, is co‑administered with SUNLENCA.</p></td></tr><tr><td style="vertical-align:top"><p>Midazolam<sup>d,i,n</sup> (2.5&nbsp;mg single dose; oral; 1 day after lenacapavir)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Midazolam:</p><p>AUC:&nbsp;&uarr;&nbsp;308%</p><p>C<sub>max</sub>: &uarr;&nbsp;116%</p><p>&nbsp;</p><p>1‑hydroxymidazolam<sup>o</sup>:</p><p>AUC: &darr;&nbsp;16%</p><p>C<sub>max</sub>: &darr;&nbsp;48%</p></td></tr><tr><td style="vertical-align:top"><p>Triazolam</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Plasma concentration of triazolam may be increased when co‑administered with lenacapavir.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTICOAGULANTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Direct Oral Anticoagulants</p><p>(DOACs)</p><p>Rivaroxaban</p><p>Dabigatran</p><p>Edoxaban</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Plasma concentration of DOAC may be increased when co‑administered with lenacapavir.</p></td><td style="vertical-align:top"><p>Due to potential bleeding risk, dose adjustment of DOAC may be required. Consult the Summary of Product Characteristics of the DOAC for further information on use in combination with combined moderate CYP3A and P‑gp inhibitors.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTIFUNGALS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Voriconazole<sup>a,b,p,q</sup> (400&nbsp;mg twice daily/200&nbsp;mg twice daily)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lenacapavir:</p><p>AUC:&uarr;&nbsp;41%</p><p>C<sub>max</sub>:&harr;</p></td><td rowspan="2" style="vertical-align:top"><p>No dose adjustment of lenacapavir is required.</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole</p><p>Ketoconazole</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Plasma concentration of lenacapavir may be increased when co‑administered with itraconazole or ketoconazole.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>H2‑RECEPTOR ANTAGONISTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Famotidine<sup>a,b</sup> (40&nbsp;mg once daily, 2 hours before lenacapavir)</p></td><td style="vertical-align:top"><p>Famotidine:</p><p>AUC:&uarr;&nbsp;28%</p><p>C<sub>max</sub>:&harr;</p></td><td style="vertical-align:top"><p>No dose adjustment of famotidine is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ORAL CONTRACEPTIVES</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Ethinylestradiol</p><p>Progestins</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Plasma concentrations of ethinylestradiol and progestins may be increased when co‑administered with lenacapavir.</p></td><td style="vertical-align:top"><p>No dose adjustment of ethinylestradiol and progestins is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>GENDER AFFIRMING HORMONES</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>17&beta;-estradiol</p><p>Anti-androgens</p><p>Progestogen</p><p>Testosterone</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Plasma concentrations of these medicinal products&nbsp; may be increased when co‑administered with lenacapavir.</p></td><td style="vertical-align:top"><p>No dose adjustment of these gender affirming hormones is required.</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fasted.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This study was conducted using lenacapavir 300&nbsp;mg single dose administered orally.</p><p>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluated as a strong inducer of CYP3A, and an inducer of P-gp and UGT.</p><p>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fed.</p><p>e&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluated as a strong inhibitor of CYP3A, and an inhibitor UGT1A1 and P-gp.</p><p>f&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluated as a moderate inducer of CYP3A and an inducer of P-gp.</p><p>g&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluated as a strong inhibitor of CYP3A and an inhibitor of P-gp.</p><p>h&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluated as a strong inhibitor of CYP3A, and an inhibitor and inducer of P-gp.</p><p>i&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This study was conducted using lenacapavir 600&nbsp;mg single dose following a loading regimen of 600&nbsp;mg twice daily for 2 days, single 600&nbsp;mg doses of lenacapavir were administered with each co‑administered medicinal product.</p><p>j&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluated as a P-gp substrate.</p><p>k&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tenofovir alafenamide is converted to tenofovir <em>in vivo</em>.</p><p>l&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluated as an OATP substrate.</p><p>m&nbsp;&nbsp;&nbsp;&nbsp; Evaluated as an BCRP substrate.</p><p>n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluated as a CYP3A substrate.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Major active metabolite of midazolam.</p><p>p&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluated as a strong inhibitor of CYP3A.</p><p>q&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This study was conducted using voriconazole 400&nbsp;mg loading dose twice daily for a day, followed by 200&nbsp;mg maintenance dose twice daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no or limited amount of data from the use of lenacapavir in pregnant women.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, foetal development, parturition or postnatal development (see section&nbsp;5.3).</p><p>&nbsp;</p><p>As a precautionary measure, it is preferable to avoid the use of SUNLENCA during pregnancy unless the clinical condition of the women requires treatment with SUNLENCA.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether lenacapavir is excreted in human milk, affects human milk production, or has effects on the breastfed infant. After administration to pregnant rats, lenacapavir was detected in the plasma of nursing rat pups, without effects on these nursing pups.</p><p>&nbsp;</p><p>Because of the potential for 1) HIV transmission (in HIV-negative infants); 2) developing viral resistance (in HIV-positive infants); and 3) adverse reactions in a breastfed infant similar to those seen in adults, instruct mothers not to breastfeed if they are receiving SUNLENCA.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no data on the effects of lenacapavir on human male or female fertility. Animal studies indicate no effects on lenacapavir on male or female fertility (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SUNLENCA is expected to have no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile </u></p><p>&nbsp;</p><p>The most common adverse reaction (all Grades) reported in at least 3% of subjects in CAPELLA was nausea.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions </u></p><p><u>&nbsp;</u></p><p>Assessment of adverse reactions is based on data from heavily treatment-experienced adult subjects with HIV who received SUNLENCA in a Phase 2/3 trial (CAPELLA; N=72) through Week 52 (median duration on study of 71 weeks) (see section 5.1), as well as supportive data in treatment-na&iuml;ve adult subjects with HIV who received SUNLENCA in a Phase 2 trial (CALIBRATE; N=157) through Week 54 (median duration of exposure of 66 weeks).</p><p><u>&nbsp;</u></p><p>A tabulated list of adverse reactions is presented in Table 4. Frequencies are defined as very common (&ge;1/10), common (&ge;1/100&nbsp;to&nbsp;&lt;1/10), uncommon (&ge;1/1,000&nbsp;to&nbsp;&lt;1/100), rare (&ge;1/10,000&nbsp;to&nbsp;&lt;1/1,000), very rare (&lt;1/10,000), and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>Table 4: Tabulated list of adverse reactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Not known</p></td><td style="vertical-align:top"><p>immune reconstitution inflammatory syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Common</p></td><td style="vertical-align:top"><p>nausea</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp; Frequencies of adverse reactions are based on all adverse events attributed to trial drug by the investigator, based on all subjects (cohorts 1 and 2) in CAPELLA.</p><p>&nbsp;</p><p>The majority (96%) of all adverse reactions associated with SUNLENCA were mild or moderate in severity.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>Immune Reconstitution Inflammatory Syndrome</em></p><p>In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section&nbsp;4.4).</p><p><strong><em>&nbsp;</em></strong></p><p><u>To reports any side effect(s):</u></p><p><u>&nbsp;</u></p><p><strong><u>Saudi Arabia:</u></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):<br />&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999<br />&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available on overdose of SUNLENCA in patients. If overdose occurs, monitor the patient for signs or symptoms of adverse reactions (see section 4.8). Treatment of overdose with SUNLENCA consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. As lenacapavir is highly bound to plasma proteins, it is unlikely to be significantly removed by dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, other antivirals, ATC code: J05AX31</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (p24) subunits in hexamers. Surface plasmon resonance sensorgrams showed dose-dependent and saturable binding of lenacapavir to cross-linked wild-type capsid hexamer with an equilibrium binding constant (KD) of 1.4 nM. Lenacapavir inhibits HIV-1 replication by interfering with multiple essential steps of the viral lifecycle, including capsid-mediated nuclear uptake of HIV-1 proviral DNA (by blocking nuclear import proteins binding to capsid), virus assembly and release (by interfering with Gag/Gag-Pol functioning, reducing production of capsid protein subunits), and capsid core formation (by disrupting the rate of capsid subunit association, leading to malformed capsids).</p><p>&nbsp;</p><p><u>Antiviral Activity in Cell Culture</u></p><p>&nbsp;</p><p>Lenacapavir has antiviral activity that is specific to human immunodeficiency virus (HIV-1 and HIV-2). The antiviral activity of lenacapavir against laboratory and clinical isolates of HIV-1 was assessed in T-lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells, and CD4<sup>+</sup> T lymphocytes with EC<sub>50</sub> values ranging from 30 to 190 pM. Lenacapavir displayed antiviral activity in cell culture against all HIV-1 groups (M, N, O), including subtypes A, A1, AE, AG, B, BF, C, D, E, F, G with EC<sub>50</sub> values ranging from 20 and 160 pM. The median EC<sub>50</sub> value for subtype B isolates (n=8) was 40 pM. Lenacapavir was 15- to 25-fold less active against HIV-2 isolates relative to HIV-1.</p><p>In a study of lenacapavir in combination with representatives from the major classes of anti-retroviral agents (INSTIs, NNRTIs, NRTIs, and PIs), no antagonism of antiviral activity was observed.</p><p><u>Resistance</u></p><p>&nbsp;</p><p><em>In cell culture</em></p><p><em>&nbsp;</em></p><p>HIV-1 variants with reduced susceptibility to lenacapavir have been selected in cell culture. Resistance selections with lenacapavir identified 7 substitutions in capsid: L56I, M66I, Q67H, K70N, N74D/S, and T107N singly or in dual combination that conferred 4- to &gt;3,226-fold reduced phenotypic susceptibility to lenacapavir relative to wild-type (WT) virus. The M66I substitution alone or in combination conferred &gt;3,226-fold decreased susceptibility to lenacapavir in a single-cycle infectivity assay; substitutions Q67H and T107N, conferred 4- to 6.3-fold decreased susceptibility; K70N, N74D and Q67H/N74S conferred 22- to 32-fold decreased susceptibility; and L56I conferred 239-fold decreased susceptibility.&nbsp;</p><p><em>In Clinical Trials</em><br /><br />In CAPELLA, 31% (22/72) of heavily treatment-experienced subjects met the criteria for resistance analyses through Week 52 (HIV-1 RNA &ge; 50 copies/mL at confirmed virologic failure [suboptimal virologic response at Week 4, virologic rebound, or viremia at last visit]) and were analyzed for lenacapavir resistance-associated substitution emergence. Lenacapavir resistance-associated capsid substitutions were found in 41% (n=9) of subjects with confirmed virologic failure who had post-baseline capsid genotypic resistance data (n=22). The M66I CA substitution was observed in 27% (6/22) of subjects, alone or in combination with other lenacapavir resistance-associated capsid substitutions including Q67Q/H, Q67Q/H/K/N, K70K/R, K70N/S, N74D, N74N/H, A105T, and T107A. The other 3 subjects with virologic failure had emergent lenacapavir resistance-associated capsid substitutions Q67K+K70H, Q67H+K70R+T107S, and Q67Q/H.&nbsp;</p><p>Phenotypic analyses of the confirmed virologic failure isolates with emergent lenacapavir resistance-associated substitutions showed 6- to &gt;1428-fold decreases in lenacapavir susceptibility when compared to WT.</p><p>Among the 9 subjects with virologic failure who developed lenacapavir resistance-associated substitutions in capsid, 4 received SUNLENCA in combination with a background regimen with no fully active antiretrovirals based on the baseline genotypic and/or phenotypic resistance. Therefore, given the risk of developing resistance in situations of functional monotherapy, careful consideration should be given to having active drugs in addition to SUNLENCA in the treatment regimen.</p><p>Four subjects with virologic failure had emergent resistance substitutions to components of the optimized background regimen (OBR): emergent NRTI substitution M184I/V and NNRTI substitution K103N/Y with emtricitabine and doravirine plus atazanavir, bictegravir, and tenofovir alafenamide in OBR; emergent NNRTI substitution V106M from a mixture at baseline (in addition to lenacapavir resistance-associated substitutions M66I + T107A) with doravirine plus emtricitabine and ibalizumab in OBR; emergent NRTI substitutions K65R and S68N from mixtures at baseline (in addition to lenacapavir resistance-associated substitution M66I) with tenofovir alafenamide, plus emtricitabine, dolutegravir, darunavir/cobistat, and rilpivirine in OBR; and emergent NRTI substitution K65K/R with tenofovir disoproxil fumarate plus darunavir/cobistat, dolutegravir, and emtricitabine in OBR.<br /><br /><u>Cross-Resistance </u></p><p>The antiviral activity in cell culture of lenacapavir was determined against a broad spectrum of HIV-1 site-directed mutants and patient-derived HIV-1 isolates with resistance to the four main classes of anti-retroviral agents (INSTI, NNRTI, NRTI, and PI; n=58), as well as to viruses resistant to the gp120-directed attachment inhibitor fostemsavir, the CD4<sup>+</sup>-directed post-attachment inhibitor ibalizumab, the CCR5 co-receptor antagonist maraviroc, and the gp41 fusion inhibitor enfuvirtide (n=42). These data indicated that lenacapavir remained fully active against all variants tested, thereby demonstrating a non-overlapping resistance profile. In addition, the antiviral activity of lenacapavir in patient isolates was unaffected by the presence of naturally occurring Gag polymorphisms and substitutions at protease cleavage sites.<br /><br /><u>Exposure-Response</u><br /><br />In CAPELLA, oral loading doses (600 mg on Day 1 and Day 2, 300 mg on Day 8) followed by subcutaneous doses (927 mg every 6 months starting on Day 15) of SUNLENCA in heavily treatment-experienced subjects with multiclass resistant HIV-1, efficacy outcomes (change in plasma HIV-1 RNA from Day 1 to Day 14, and percentage of subjects with HIV-1 RNA less than 50 copies/mL at Week 26) were similar across the range of observed lenacapavir exposures.<br /><br /><u>Cardiac Electrophysiology</u><br /><br />At supratherapeutic exposures of lenacapavir (9-fold higher than the therapeutic exposures of SUNLENCA), SUNLENCA does not prolong the QTcF interval to any clinically relevant extent.</p><p><u>Clinical data</u><br /><br />The efficacy and safety of SUNLENCA in HIV-1 infected, heavily treatment-experienced subjects with multidrug resistance is based on 52-week data from CAPELLA, a randomized, placebo-controlled, double-blind, multicenter trial (NCT 04150068).</p><p><u>&nbsp;</u></p><p>CAPELLA was conducted in 72 heavily treatment-experienced subjects with multiclass resistant HIV-1. Subjects were required to have a viral load &ge; 400 copies/mL, documented resistance to at least two antiretroviral medications from each of at least 3 of the 4 classes of antiretroviral medications (NRTI, NNRTI, PI and INSTI), and &le; 2 fully active antiretroviral medications from the 4 classes of antiretroviral medications remaining at baseline due to resistance, intolerability, drug access, contraindication, or other safety concerns.<br /><br />The trial was composed of two cohorts. Subjects were enrolled into the randomized cohort (cohort 1, N=36) if they had a &lt; 0.5 log<sub>10</sub> HIV-1 RNA decline compared to the screening visit. Subjects were enrolled into the non-randomized cohort (cohort 2, N=36) if they had a &ge; 0.5 log<sub>10</sub> HIV-1 RNA decline compared to the screening visit or after cohort 1 reached its planned sample size.<br /><br />In the 14-day functional monotherapy period, subjects in cohort 1 were randomized in a 2:1 ratio in a blinded fashion to receive either SUNLENCA or placebo, while continuing their failing regimen. This period was to establish the virologic activity of SUNLENCA. After the functional monotherapy period, subjects who had received SUNLENCA continued on SUNLENCA along with an optimized background regimen (OBR); subjects who had received placebo during this period initiated SUNLENCA along with an OBR.<br /><br />Subjects in cohort 1 had a mean age of 52 years (range: 24 to 71), 72% were male, 46% were White, 46% were Black, and 9% were Asian. 29% percent of subjects identified as Hispanic/Latino. The mean baseline plasma HIV-1 RNA was 4.3 log<sub>10</sub> copies/mL (range:&nbsp;2.3 to 5.4). 19% of subjects had baseline viral loads greater than 100,000 copies/mL. The mean baseline CD4<sup>+</sup> cell count was 161 cells/mm<sup>3</sup> (range: 6 to 827). 75% of subjects had CD4<sup>+</sup> cell counts below 200 cells/mm<sup>3</sup>.<sup> </sup>The mean number of years since subjects first started HIV treatment was 24 years (range: 7 to 33); the mean number of antiretroviral agents in failing regimens at baseline was 4 (range: 1 to 7). The percentage of subjects in the randomized cohort with known resistance to at least 2 agents from the NRTI, NNRTI, PI and INSTI classes was 97%, 94%, 78% and 75%, respectively. In cohort 1, 53% of subjects had no fully active agents, 31% had 1 fully active agent, and 17% had 2 or more fully active agents within their initial failing regimen, including 6% of subjects were who were receiving fostemsavir, which was an investigational agent at the start of the CAPELLA trial.<br /><br />Subjects in cohort 2 initiated SUNLENCA and an OBR on Day 1.<br /><br />Subjects in cohort 2 had a mean age of 48 years (range: 23 to 78), 78% were male, 36% were White, 31% were Black, 33% were Asian, and 14% of subjects identified as Hispanic/Latino. The mean baseline plasma HIV-1 RNA was 4.1 log<sub>10</sub> copies/mL (range:&nbsp;1.3 to 5.7). 19% of subjects had baseline viral loads greater than 100,000 copies/mL. The mean baseline CD4<sup>+</sup> cell count was 258 cells/mm<sup>3</sup> (range: 3 to 1296). 53% of subjects had CD4<sup>+</sup> cell counts below 200 cells/mm<sup>3</sup>.<sup> </sup>The mean number of years since subjects first started HIV treatment was 19 years (range: 3 to 35); the mean number of antiretroviral agents in failing regimens at baseline was 4 (range: 2 to 7). The percentage of subjects in the non-randomized cohort with known resistance to at least 2 agents from the NRTI, NNRTI, PI and INSTI classes was 100%, 100%, 83% and 64%, respectively. In cohort 2, 31% of subjects had no fully active agents, 42% had 1 fully active agent, and 28% had 2 or more fully active agents within their initial failing regimen, including 6% of subjects who were receiving fostemsavir, which was an investigational agent at the start of the CAPELLA trial.<br /><br />The primary efficacy endpoint was the proportion of subjects in cohort 1 achieving &ge; 0.5 log<sub>10</sub> copies/mL reduction from baseline in HIV-1 RNA at the end of the functional monotherapy period. The results of the primary endpoint analysis are shown in <!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'><span style='mso-element:field-begin;
mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>REF
_Ref74903212 \h<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->Table&nbsp;5<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000D0000005F00520065006600370034003900300033003200310032000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'><span style='mso-element:field-end'></span></span><![endif]-->.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>5 </strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; Proportion of Subjects Achieving a &ge; 0.5 log<sub>10</sub> Decrease in Viral Load at the End of the Functional Monotherapy Period in the CAPELLA Trial (Cohort 1)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>SUNLENCA<br />(N=24)</p></td><td style="vertical-align:bottom"><p>Placebo<br />(N=12)</p></td></tr></thead><tbody><tr><td><p>Proportion of Subjects Achieving a &ge; 0.5 log<sub>10</sub> Decrease in Viral Load</p></td><td><p>87.5%</p></td><td><p>16.7%</p></td></tr><tr><td><p>Treatment Difference (95% CI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td colspan="2"><p>70.8% (34.9% to 90.0%) <sup>a</sup></p></td></tr></tbody></table><p><strong><sup>&nbsp;&nbsp; </sup></strong>a. &nbsp;&nbsp;&nbsp; p &lt; 0.0001<br />&nbsp;</p><p>The results at Weeks 26 and 52 are provided in <!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>REF _Ref74903288 \h<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]-->Table&nbsp;6<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000D0000005F00520065006600370034003900300033003200380038000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--> and <!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin;
mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>REF
_Ref74903298 \h<span style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->Table&nbsp;7<!--[if gte mso 9]><xml>
 <w:data>08D0C9EA79F9BACE118C8200AA004BA90B02000000080000000D0000005F00520065006600370034003900300033003200390038000000</w:data>
</xml><![endif]--><!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]-->.</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;</strong><strong>6</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Virologic Outcomes (HIV-1 RNA &lt; 50 copies/mL) at Weeks 26<sup> a</sup> and<br />52 <sup>b</sup> with SUNLENCA plus OBR in the CAPELLA Trial (Cohort 1)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="2" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2"><p>SUNLENCA plus OBR<br />(N=36)</p></td></tr><tr><td><p>Week 26</p></td><td><p>Week 52</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>HIV-1 RNA &lt; 50 copies/mL</p><p>&nbsp;</p></td><td><p>81%</p></td><td><p>83%</p></td></tr><tr><td style="vertical-align:top"><p>HIV-1 RNA &ge; 50 copies/mL<sup>c</sup></p></td><td><p>19%</p></td><td><p>14%</p></td></tr><tr><td style="vertical-align:top"><p>No virologic data in Week 26 or 52 Window</p></td><td><p>0</p></td><td><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued Study Drug Due to AE or Death <sup>d</sup></p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued Study Drug Due to Other Reasons <sup>e </sup>and Last Available HIV-1 RNA &lt;&nbsp;50&nbsp;copies/mL</p></td><td><p>0</p></td><td><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Missing Data During Window but on Study&nbsp;Drug</p></td><td><p>0</p></td><td><p>0</p></td></tr></tbody></table><p>OBR = optimized background regimen</p><p>a. &nbsp;&nbsp;&nbsp; Week 26 window was between Days 184 and 232 (inclusive).</p><p>b. &nbsp;&nbsp;&nbsp; Week 52 window was between Days 324 and 414 (inclusive).</p><p>c. &nbsp;&nbsp;&nbsp; Includes subjects who had &ge; 50 copies/mL in the Week 26 or 52 window; subjects who discontinued early due to lack or loss of efficacy; subjects who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of &ge; 50 copies/mL.</p><p>d. &nbsp;&nbsp;&nbsp; Includes subjects who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.</p><p>e. &nbsp;&nbsp;&nbsp; Includes subjects who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up, etc.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>7</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Virologic Outcomes (HIV-1 RNA &lt; 50 copies/mL) by Baseline Covariates at Weeks 26<sup> a</sup> and 52<sup>b </sup>with SUNLENCA plus OBR in the CAPELLA trial (Cohort 1)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><thead><tr><td rowspan="2" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2"><p>SUNLENCA plus OBR<br />(N=36)</p></td></tr><tr><td><p>Week 26</p></td><td><p>Week 52</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Age (Years)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 50</p></td><td><p>100% (9/9)</p></td><td><p>89% (8/9)</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 50</p></td><td><p>74% (20/27)</p></td><td><p>81% (22/27)</p></td></tr><tr><td style="vertical-align:top"><p>Gender</p></td><td colspan="2">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Male</p></td><td><p>77% (20/26)</p></td><td><p>77% (20/26)</p></td></tr><tr><td style="vertical-align:top"><p>Female</p></td><td><p>90% (9/10)</p></td><td><p>100% (10/10)</p></td></tr><tr><td style="vertical-align:top"><p>Race</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Black</p></td><td><p>81% (13/16)</p></td><td><p>75% (12/16)</p></td></tr><tr><td style="vertical-align:top"><p>Non-Black</p></td><td><p>84% (16/19)</p></td><td><p>89% (17/19)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline plasma viral load (copies/mL)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&le; 100,000</p></td><td><p>86% (25/29)</p></td><td><p>86% (25/29)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 100,000</p></td><td><p>57% (4/7)</p></td><td><p>71% (5/7)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline CD4<sup>+</sup> (cells/mm<sup>3</sup>)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 200</p></td><td><p>78% (21/27)</p></td><td><p>78% (21/27)</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 200</p></td><td><p>89% (8/9)</p></td><td><p>100% (9/9)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline INSTI resistance profile</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>With INSTI resistance</p></td><td><p>85% (23/27)</p></td><td><p>81% (22/27)</p></td></tr><tr><td style="vertical-align:top"><p>Without INSTI resistance</p></td><td><p>63% (5/8)</p></td><td><p>88% (7/8)</p></td></tr><tr><td style="vertical-align:top"><p>Number of fully active ARV agents in the OBR</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td><p>67% (4/6)</p></td><td><p>67% (4/6)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td><p>86% (12/14)</p></td><td><p>79% (11/14)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 2</p></td><td><p>81% (13/16)</p></td><td><p>94% (15/16)</p></td></tr><tr><td style="vertical-align:top"><p>Use of DTG and/or DRV in the OBR</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>With DTG and DRV</p></td><td><p>83% (10/12)</p></td><td><p>83% (10/12)</p></td></tr><tr><td style="vertical-align:top"><p>With DTG, without DRV</p></td><td><p>83% (5/6)</p></td><td><p>83% (5/6)</p></td></tr><tr><td style="vertical-align:top"><p>Without DTG, with DRV</p></td><td><p>78% (7/9)</p></td><td><p>89% (8/9)</p></td></tr><tr><td style="vertical-align:top"><p>Without DTG or DRV</p></td><td><p>78% (7/9)</p></td><td><p>78% (7/9)</p></td></tr></tbody></table><p>ARV = antiretroviral; DRV=darunavir; DTG=dolutegravir; INSTI = integrase strand-transfer inhibitor; OBR = optimized background regimen;<br />a.&nbsp;&nbsp;&nbsp;&nbsp; Week 26 window was between Days 184 and 232 (inclusive).<br />b.&nbsp;&nbsp;&nbsp;&nbsp; Week 52 window was between Days 324 and 414 (inclusive).</p><p>&nbsp;</p><p>In cohort 1, at Weeks 26 and 52, the mean change from baseline in CD4<sup>+</sup> cell count was 81 cells/mm<sup>3</sup> (range: ‑101 to 522) and 82 cells/mm<sup>3</sup> (range: -194 to 467), respectively.</p><p>In cohort 2, at Week 26 and 52, 81% (29/36) and 72% (26/36) of patients achieved HIV-1 RNA &lt; 50 copies/mL, respectively, and the mean change from baseline in CD4<sup>+</sup> cell count was 97 cells/mm<sup>3</sup> (range: -103 to 459) and 113 cells/mm<sup>3</sup> (range: -124 to 405), respectively.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p><em>Oral Administration</em></p><p>Lenacapavir is absorbed following oral administration with peak plasma concentrations occurring 4 hours after administration of SUNLENCA. Absolute bioavailability following oral administration of lenacapavir is low (approximately 6% to 10%). Lenacapavir is a substrate of P-gp.</p><p>&nbsp;</p><p>Lenacapavir AUC, C<sub>max</sub> and T<sub>max</sub> were comparable following administration of a low fat (~400 kcal, 25% fat) or high fat (~1000 kcal, 50% fat) meal relative to fasted conditions. Oral lenacapavir can be administered without regard to food.</p><p>&nbsp;</p><p><em>Subcutaneous Administration</em></p><p>Lenacapavir is completely absorbed following subcutaneous administration. Due to slow release from the site of subcutaneous administration, the absorption profile of subcutaneously administered lenacapavir is complex with peak plasma concentrations occurring 77 to 84 days postdose.</p><p>&nbsp;</p><p><em>Pharmacokinetic Parameters</em></p><p>The population pharmacokinetic parameter estimates of SUNLENCA after oral and subcutaneous administration are provided in Table 8.</p><p>&nbsp;</p><p><strong>Table 8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lenacapavir Exposures Following Oral and Subcutaneous Administration of SUNLENCA in Heavily Treatment Experienced Subjects with HIV </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td rowspan="3" style="vertical-align:bottom"><p>Parameter<br />Mean (%CV)</p></td><td style="vertical-align:bottom"><p>Recommended Dosing Regimen,<br />Option 1 <sup>a</sup></p></td><td colspan="2" style="vertical-align:bottom"><p>Recommended Dosing Regimen,<br />Option 2 <sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Day 1: 600 mg (oral) + 927 mg (SC)</p><p>Day 2: 600 mg (oral)</p></td><td colspan="2" style="vertical-align:bottom"><p>Days 1 and 2: 600 mg (oral),</p><p>Day 8: 300 mg (oral),</p><p>Day 15: 927 mg (SC)</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p><p>Day 1 to end of Month 6</p></td><td style="vertical-align:bottom"><p>Days 1 to 15</p></td><td style="vertical-align:bottom"><p>Day 15 to end of Month&nbsp;6</p></td></tr><tr><td><p>C<sub>max</sub><br />(ng/mL)</p></td><td><p>97.1 (61.6)</p></td><td><p>124.4 (85.1)</p></td><td><p>87.3 (49.4)</p></td></tr><tr><td><p>AUC<sub>tau</sub><br />(h&bull;ng/mL)</p></td><td><p>234294.8 (65.1)</p></td><td><p>25962.9 (67.8)</p></td><td><p>251907.2 (48.2)</p></td></tr><tr><td><p>C<sub>trough </sub></p><p>(ng/mL)</p></td><td><p>29.2 (90.8)</p></td><td><p>48.6 (52.1)</p></td><td><p>35.1 (59.2)</p></td></tr></tbody></table><p>CV = coefficient of variation; NA = not applicable; SC = subcutaneous</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Predicted exposures.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Post hoc exposures from CAPELLA (N=62).</p><p>&nbsp;</p><p>The estimated exposures of lenacapavir were 43% to 100% higher in subjects with HIV-1 infection compared to subjects without HIV-1 infection.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The apparent volume of distribution was 19240 litres after oral administration, and ranged from 9500 to 11700 litres after subcutaneous administration.</p><p>&nbsp;</p><p>Lenacapavir is highly bound to plasma proteins (&gt; 98.5%).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Following a single intravenous dose of radiolabeled-lenacapavir to healthy subjects, 76% of the total radioactivity was recovered from feces and &lt; 1% from urine. Unchanged lenacapavir was the predominant moiety in plasma (69%) and feces (33%). Metabolism played a lesser role in lenacapavir elimination. Lenacapavir was metabolized via oxidation, N-dealkylation, hydrogenation, amide hydrolysis, glucuronidation, hexose conjugation, pentose conjugation, and glutathione conjugation; primarily via CYP3A and UGT1A1. No single circulating metabolite accounted for &gt; 10% of plasma drug-related exposure.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>The median half-life following oral and subcutaneous administration ranged from 10 to 12 days, and 8 to 12 weeks, respectively. Mean apparent clearance was 55 L/h following oral administration and 4.2 L/h following subcutaneous administration.</p><p>&nbsp;</p><p><u>Linearity/Non-linearity</u></p><p><u>&nbsp;</u></p><p>The single dose pharmacokinetics of lenacapavir after oral administration are non-linear and less than dose proportional over the dose range of 50 to 1800 mg.</p><p>&nbsp;</p><p>The single dose pharmacokinetics of lenacapavir after subcutaneous injection (309 mg/mL) are dose proportional over the dose range of 309 to 927 mg.</p><p>&nbsp;</p><p><u>Other special populations</u></p><p>&nbsp;</p><p>There were no clinically significant differences in the pharmacokinetics of lenacapavir based on age (18 to 78 years), sex, ethnicity, race (white, black, asian or other), body weight (41.4 to 164 kg), severe renal impairment (creatinine clearance of 15 to less than 30 mL per minute, estimated by Cockroft-Gault method), or moderate hepatic impairment (Child-Pugh Class B). The effect of end-stage renal disease (including dialysis), or severe hepatic impairment (Child-Pugh Class C), on the pharmacokinetics of lenacapavir is unknown. As lenacapavir is greater than 98.5% protein bound, dialysis is not expected to alter exposures of lenacapavir<em>.</em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, toxicity to reproduction and development.</p><p>&nbsp;</p><p><u>Carcinogenesis</u></p><p>Lenacapavir was not carcinogenic in a 6-month rasH2 transgenic mouse study in males or females at doses of up to 300 mg/kg/dose once every 13 weeks. A 2-year rat carcinogenicity study is ongoing.<br />&nbsp;</p><p><u>Mutagenesis</u></p><p><br />Lenacapavir was not mutagenic in a battery of <em>in vitro</em> and <em>in vivo</em> genotoxicity assays, including microbial mutagenesis, chromosome aberration in human peripheral blood lymphocytes, and in <em>in vivo</em> rat micronucleus assays.</p><p><u>&nbsp;</u></p><p><u>Impairment of Fertility</u></p><p>&nbsp;</p><p>There were no effects on fertility, mating performance or early embryonic development when lenacapavir was administered to rats at systemic exposures (AUC) 5 times the exposure to humans at the recommended human dose of SUNLENCA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p><u>&nbsp;</u></p><p>Copovidone</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p><p>Mannitol</p><p>Microcrystalline cellulose</p><p>Poloxamer 407</p><p><u>&nbsp;</u></p><p><u>Film-coating</u></p><p><u>&nbsp;</u></p><p>Iron oxide black</p><p>Iron oxide red</p><p>Iron oxide yellow</p><p>Polyethylene glycol</p><p>Polyvinyl alcohol</p><p>Talc</p><p>Titanium dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SUNLENCA tablets are packaged in child-resistant clear PVC/aluminium/paperboard blister. The blister is packaged with silica gel desiccant in a flexible laminated pouch. The following pack sizes are available: 4 tablets and 5 tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gilead Sciences, Inc.
333 Lakeside Drive,
Foster City, CA 94404
United States

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2023

SA-FEB2023-US-DEC2022-EU-AUG2022

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>